Pancreatic cancer trial combines immunotherapy and targeted drug to boost treatment
NCT ID NCT03727880
First seen Feb 04, 2026 · Last updated May 12, 2026 · Updated 12 times
Summary
This study tested whether adding two drugs—pembrolizumab (an immunotherapy) and defactinib (a targeted therapy)—to standard chemotherapy could help the immune system fight pancreatic cancer better. The treatment was given before and after surgery to 28 people with resectable pancreatic cancer. The main goal was to see if the cancer disappeared completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samuel Oschin Cancer Center at Cedars-Sinai
Los Angeles, California, 90048, United States
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
The University of Texas Health Science Center San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.